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1036Alternate Donor Hematopoietic Cell Transplantation
(HCT) in Non-Hodgkin Lymphoma Using Lower
Intensity Conditioning: A Report from the CIBMTR
Gregory A. Hale,1 Smriti Shrestha,2 Jennifer Le-Rademacher,2 Linda J. Burns,3 John Gibson,4
David J. Inwards,5 Cesar O. Freytes,6 Brian J. Bolwell,7 Jack W. Hsu,8 Shimon Slavin,9
Luis Isola,10 David A. Rizzieri,11 Robert Peter Gale,12 Ginna G. Laport,13 Silvia Montoto,14
Hillard M. Lazarus,15 Parameswaran N. Hari2We analyzed the outcomes of 248 (61% male) adult recipients of HLA-matched unrelated and HLA-
mismatched related donor hematopoietic cell transplantation (HCT) for non-Hodgkin lymphoma (NHL)
after reduced or lower intensity conditioning (RIC), reported to the Center for International Blood and Mar-
row Transplant Research (CIBMTR) from 1997 to 2004. Median age was 52 (range: 18-72 years); 31% had
a Karnofsky performance score\90. Follicular NHL (43%) was the major histology. Incidence of grades
II-IV acute graft-versus-host disease (aGVHD) was 43% at 100 days; and chronic GVHD (cGVHD) was
44% at 3 years. Treatment-related mortality (TRM) at 100 days was 24%. Three-year overall survival (OS)
and progression-free survival (PFS) were 41% and 32%, respectively. In multivariate analysis, use of antithy-
mocyte globulin (ATG) and HLA mismatch were associated with increased TRM. High-grade histology, ATG
use, and chemotherapy resistance were associated with lower PFS. Older age, shorter interval from diagno-
sis to HCT, non–total body irridiation (TBI) conditioning regimens, ex vivo T cell depletion, and HLA-
mismatched unrelated donors were associated with mortality. GVHD did not influence relapse or PFS. Older
age, aggressive histology, and chemotherapy resistance correlated with poorer survival. For selected patients
with NHL, lack of an available sibling donor should not be a barrier to allogeneic HCT.
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Allogeneic hematopoietic cell transplantation
(HCT) can be curative for those with high-risk or rec-
urrent hematologic cancers including non-Hodgkin
lymphoma (NHL) [1,2]. For patients lacking an
HLA-matched related donor, alternative hematopoietic
cell sources include HLA-matched unrelated donors
and HLA-mismatched related donors [3,4]. Over the
past decade, traditional myeloablative conditioning
has been increased replaced by lower intensity
conditioning in an effort to reduce treatment-related
mortality (TRM). The possibility of lower regimen-
related toxicity makes these regimens particularly
attractive for older persons and those with comorbid-
ities. Lower intensity conditioning regimens have
been extended to older patients, employing alternative
donors and all hematopoietic cell sources including
cord blood cells. Most published experience with these
regimens in NHL patients, particularly their outcomes
with respect to disease recurrence and TRM, is limited
to single-institution studies with few patients.With this
inmind, we performed a noncomparative, retrospective
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alternate donor HCT for NHL following a variety of
lower intensity conditioning regimens commonly
referred to as reduced-intensity conditioning (RIC).METHODS
Data Collection
Data used in this study were obtained from the
Statistical Center of the Center for International
Blood and Marrow Transplant Research (CIBMTR).
CIBMTR is a research affiliation of the International
Bone Marrow Transplant Registry and the National
Marrow Donor Program that comprises a voluntary
working group of more than 450 transplantation
centers worldwide that contribute detailed data on
consecutive allogeneic and autologous HCT to a Sta-
tistical Center at the Medical College of Wisconsin in
Milwaukee and the National Marrow Donor Program
Coordinating Center in Minneapolis. Participating
centers are required to report all consecutive trans-
plants; compliance is monitored by on-site audits.
Subjects are followed longitudinally, with yearly
follow-up. Computerized checks for errors, physi-
cians’ review of submitted data, and on-site audits of
participating centers ensure data quality. Observa-
tional studies conducted by the CIBMTR are done
with a waiver of informed consent and in compliance
with HIPAA regulations as determined by the institu-
tional review board and the Privacy Officer of the
Medical College of Wisconsin.
Study Population
This study was restricted to adult subjects ($18
years) with NHL undergoing a first allogeneic HCT
with an RIC regimen from 1997 to 2004. Subjects re-
ceiving allogeneic HCT after relapse from prior auto-
logous HCT and cord blood graft recipients were
excluded. The classification of degree of HLA match
was based on the previously validatedmodel for group-
ing the degree of HLA match proposed by Weisdorf
et al. [5,6]. In this schema, ‘‘partially matched’’ cases
were missing either high-resolution or HLA-C data
or had a defined single-locus mismatch. Mismatched
unrelated cases had $2 allele or antigen mismatches.
The study population included 248 subjects with
NHL, with the following characteristics: 26 (10%)
received HLA-mismatched related grafts, 151 (61%)
matched unrelated grafts, 47 (19%) partially matched
unrelated grafts, and 24 (9%) received mismatched
unrelated donor grafts according to criteria proposed
by Weisdorf et al. [6]. Definitions and categorization
of conditioning regimens were assigned according to
consensus criteria [7,8]. Regimens that did not
involve full myeloablative chemo/radiation therapy
were included in the schema of RIC for this analysis.All subjects received calcineurin-based GVHD pro-
phylaxis with or without methotrexate. The follow-
up completeness index for this study cohort was
90%. Patient-, disease-, and transplant-related charac-
teristics are listed in Table 1.
Endpoints and Definitions
The primary objective was to describe the out-
comes after allogeneic HCT for NHL using RIC reg-
imens and alternate donor grafts. We analyzed time to
engraftment, incidence of acute and chronic GVHD
(aGVHD, cGVHD), relapse, TRM, progression-free
survival (PFS) and overall survival (OS). Neutrophil
engraftment was defined as the first of 3 consecutive
days with an absolute neutrophil count of $0.5 
109/L; platelet engraftment was defined as platelet
count $20  109/L for 7 consecutive days without
transfusion support. TRM was defined as death from
any cause in the first 28 days or death without evidence
of lymphoma progression/relapse. Progression was
defined as an increase of $25% in the sites of lym-
phoma or development of new sites of lymphoma.
Relapse was defined as recurrence of lymphoma after
a complete response. For calculating PFS, patients
were considered treatment failures at relapse or pro-
gression or death. Patients alive without evidence of
disease relapse or progression were censored at last
follow-up, and PFS was summarized by a survival
curve. The OS interval variable was defined as the
time from date of transplantation to date of death or
last contact, and summarized by a survival curve. Other
outcomes analyzed included aGVHD and cGVHD
and cause of death. Acute GVHD was defined and
graded based on the pattern and severity of organ
involvement using established criteria [9]. Chronic
GVHD was defined as the development of any
cGVHD based on clinical criteria [10]. Both these
events were summarized by the corresponding cumu-
lative incidence estimate, with death without develop-
ment of GVHD as the competing risk.
Statistical Analysis
Patient-, disease-, and transplant-related variables
(Table 1) were described with median and range for
continuous variables, and percent of total for categoric
variables. Occurrence of aGVHDand cGVHD,TRM,
and disease recurrence/progressionwere calculated us-
ing cumulative incidence estimates, taking into account
the competing risk [11]. Probabilities of PFS and OS
were estimated from the time of transplantation using
the Kaplan-Meier estimator [12].
Associations among patient-, disease-, and
transplant-related factors and outcomes of interest
were assessed using multivariate Cox proportional
hazards regression. A stepwise forward selection mul-
tivariate model was built to identify covariates that
Table 1. Characteristics of Adult Subjects Receiving Alloge-
neic HCT from Unrelated or HLA-Mismatched Family Mem-
ber Donors with a Reduced-Intensity or Nonmyeloablative
ConditioningRegimen forNHLReported to theCIBMTR from
1997 to 2004
Variables N (%)
Patient related
Age, median (range), years 52 (18-72)
Male sex 152 (61)
Karnofsky score pretransplantation
<90 78 (31)
Disease related
Disease stage at diagnosis
I 21 (8)
II 37 (15)
III 45 (18)
IV 133 (54)
Missing 12 (5)
Time from diagnosis to transplantation,
median (range), months
29 (4-196)
<12 months 25 (10)
12-24 months 74 (30)
$24 months 149 (60)
Histology
Follicular 107 (43)
DLCL/immunoblastic 58 (24)
Lymphoblastic/Burkitt’s/Burkitt-like 55 (22)
Mantle cell 12 (5)
PTCL 16 (6)
Transplantation related
Disease stage at transplantation
I 122 (49)
II 54 (22)
CR 72 (29)
Disease status at transplantation
CR2+ 43 (17)
PIF sensitive 48 (19)
PIF resistant 26 (10)
REL sensitive 58 (23)
REL resistant 52 (21)
REL untreated/unknown 21 (9)
Chemo sensitivity at transplantation
Sensitive 127 (51)
Resistant 95 (38)
Not evaluable 26 (10)
Prior radiation before transplantation 69 (28)
TBI-based conditioning regimen 49 (21)
Marrow grafts 106 (43)
Conditioning regimen
FludMEL ± ATG 49 (20)
FludBu ± ATG 31 (12)
FludBu ± TLI 10 (4)
Flud + Cy ± Rituxan 61 (25)
Flud + TBI 5 200 cGY 27 (11)
BuCy (reduced) 5 (2)
BEAM/similar 14 (6)
TBI only 18 (7)
VP16 + Cy 1 (<1)
CBV 19 (8)
Other 13 (5)
Number of lines of therapy, median (range), months 4 (1-6)
Donor type (HLA match)
Unrelated well matched 151 (61)
Unrelated partially matched 47 (19)
Mismatched family member donors 26 (10)
Unrelated mismatched 24 (9)
Donor-recipient gender match
Male-male 108 (44)
Male-female 58 (23)
Female-male 44 (18)
Female-female 38 (15)
Donor-recipient CMV status
+/+ 48 (19)
(Continued )
Table 1. (Continued )
Variables N (%)
+/2 14 (6)
2/+ 75 (30)
2/2 87 (35)
Year of transplantation
1997-1998 7 (3)
1999-2000 40 (16)
2001-2002 80 (32)
2003-2004 121 (49)
ATG in conditioning 74 (30)
GVHD prophylaxis
T cell depletion ± other (ex vivo) 11 (4)
FK506 + MTX ± other 98 (40)
FK506 ± other 44 (18)
CsA + MTX ± other 32 (13)
CsA ± other 61 (24)
Other/unknown 2 (1)
DLCL indicates diffuse large cell lymphoma; PTCL, peripheral T cell lym-
phoma; PIF, primary induction failure; CR, complete remission; REL,
relapse; MEL, melphalan; Flud, fludarabine; Bu, busulfan; Cy, cyclophos-
phamide; CBV, cyclophosphamide + BCNU + VP16 5 etoposide; BM,
bone marrow; PBSC, peripheral blood stem cell; CsA, cyclosporine;
FK506, tacrolimus; MTX, methotrexate; CMV, cytomegalovirus.
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were considered significant. The proportionality as-
sumption for Cox regression was tested by adding
a time-dependent covariate for each risk factor and
each outcome, and then interactions between the
type of donor and the other covariates were checked.
Covariates that violated the proportional hazard as-
sumption were adjusted by stratification. Results
were expressed as relative risk (RR) or the relative
rate of occurrence of the event. Stepwise forward-
backward selection was used to build the models
from the prognostic factors under consideration. All
P values were 2 sided. All analyses were performed
using SAS 9.1 (SAS Institute, Cary, NC). The
multivariate analyses are summarized in Table 2.RESULTS
Subjects, Disease, Transplant Characteristics
Median age was 52 years (range: 18-72 years); 31%
had a Karnofsky performance score\90. Median fol-
low up was 44 months (range: 1-123 months).Engraftment
Incidence of neutrophil engraftment at day 28 and
day 100 after HCT was 92% (95% confidence interval
[CI]; 88%-95%) and 94% (95% CI; 90%-96%), re-
spectively. Fifty percent of patients received myeloid
growth factors after HCT. The incidents of platelet
engraftment at day 28 and day 100 after HCT were
67% (95% CI; 61%-73%) and 79% (95% CI; 73%-
83%), respectively. Fifteen subjects had primary graft
failure, and 33 had secondary graft failure.
Table 2. Variables Considered in Multivariate Analysis
Patient related:
Age at transplantation: #60 years* versus >60 years
Karnofsky performance at transplantation: <90%* versus $90% versus
missing
Gender: male* versus female
Disease related:
Histologic type of NHL
Immunophenotype: B cell* versus T cell versus missing
Time from diagnosis to transplantation: <12 months* versus$24 months
versus 12-24 months
Number of lines of therapy: #2* versus 3-4 versus $5
Disease status at transplantation: CR2* versus PIF sens versus PIF res
versus Rel sens versus Rel res
Rel untreated/unknown/missing
Chemosensitive disease at transplantation: Sensitive* versus resistant
versus not evaluable/untreated/missing
Marrow involvement at diagnosis: yes* versus no
Duration of CR1: continuous
Transplantation related:
Conditioning regimen: TBI* versus non-TBI
Conditioning regimen: ATG given versus no ATG given*
Donor type/HLA match: Unrelated well matched* versus unrelated
partially matched versus unrelated mismatched versus mismatched
family member donor
Source of stem cells: Bone marrow* versus peripheral blood
GVHD prophylaxis: FK506 + MTX ± others* versus MTX + CsA + others
versus CsA + others versus T cell depletion + others versus FK506 ±
other
Donor-recipient CMV status: +/+* versus +/2 versus 2/+ versus 2/2
Donor-recipient gender match: M-M* versus M-F versus F-M versus F-F
Year of transplantation: 1997-2000* versus 2001-2002 versus 2003-2004
DLCL indicates diffuse large cell lymphoma; PTCL, peripheral T cell
lymphoma; PIF, primary induction failure; CR, complete remission;
REL, relapse; res, resistant; sens, sensitive; TBI, total body radiation;
GVHD, graft versus host disease; CsA, cyclosporine; FK506, tacrolimus;
MTX, methotrexate; CMV, cytomegalovirus; M, male; F, female.
Table 3. Multivariate Analysis
Variables Relative Risk (95% CI) P Value
TRM
ATG: Yes versus No 2.13 (1.40-3.25) <.001
Donor type: Unrelated mismatched
versus well matched
2.07 (1.17-3.84) .02
Relapse
Age: >60 versus #60 1.93 (1.07-3.48) .028
Histology: Diffuse large B cell versus
follicular
3.46 (1.80-6.34) <.001
Status: REL resistant versus CR2+ 5.05 (2.13-11.99) <0.001
Year of transplantation: 2003-2004
versus 1997-2000
2.87 (1.25-6.58) .013
Risk of treatment failure
Histology: lymphoblastic/Burkitts/
Burkitt-like versus follicular
2.11 (1.40-3.18) <.001
Status: REL resistant versus CR2+ 2.54 (1.50-4.31) .001
ATG: Yes versus no 1.50 (1.07-2.10) .020
Time from diagnosis to
transplantation: 12-24 months
versus $24
1.58 (1.09-2.31) 0.017
Risk of mortality
Age: >60 versus #60 1.77 (1.16-2.70) .009
Time from diagnosis to
transplantation: 12-24 months
versus $24
2.26 (1.56-3.27) <.001
TBI: No versus yes 2.17 (1.36-3.48) .001
Donor type: unrelated mismatched
versus well matched
2.20 (1.24-3.90) .007
GVHD prophylaxis: ex vivo T cell
depletion versus FK506/MTX
6.0 (2.68-13.45) <.001
ATG indicates antithymocyte globulin; REL, relapse; CR, complete
remission; FK506, tacrolimus; MTX, methotrexate.
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The incidence of grade II-IV aGVHD was 43%
(95% CI; 37%-49%). The incidence of cGVHD was
36% (95% CI; 30%-42%) at 1 year and 44% (95% CI;
37%-50%) at 3 years. Recipients of HLA-mismatched
unrelated donor grafts had a greater risk of aGVHD
(hazard ratio [HR] 5 2.70; 95% CI; 1.50-4.84; P \
.001) in multivariate analysis. The use of total body
irridiation (TBI) increased the risk of cGVHD (HR 5
1.62; 95% CI; 1.05-2.49; P 5 .03). GVHD was the
primary cause of death in 23 subjects (15%).Relapse
Cumulative incidents of lymphoma progression or
relapse at 1, 3, and 5 years post-HCT were 26% (95%
CI; 20%-31%), 30% (95% CI; 24%-36%), and 31%
(95% CI; 26%-38%), respectively. Older age (.60
years) (RR 5 1.93; 95% CI; 1.07-3.48; P 5 .028), dif-
fuse large cell histology (RR 5 3.46; 95% CI; 1.80-
6.34), and resistant relapsed disease status at HCT
(RR 5 5.05; 95% CI; 2.13-11.99) were associated
with a higher risk of progression/relapse (Table 3).
Patients transplanted in the most recent years
(2003-2004) had a higher risk of progression/relapse
(HR 5 2.87; 95% CI; 1.26-6.58; P 5 .013). GVHDdid not correlate with disease progression or relapse.
Median interval from HCT to relapse was 6 months.TRM
TRM at 28 and 100 days post-HCT was 11%
(95% CI; 7%-15%) and 24% (95% CI 5 19%-
30%), respectively. TRM gradually increased from
31% (95% CI; 25%-37%) at 1 year to 39% (95%
CI; 32%-45%) at 3 years, to 43% (95% CI; 36%-
50%) at 5 years post-HCT. Use of antithymocyte
globulin (ATG) (RR 5 2.13; 95% CI; 1.40-3.25; P\
.001), HLA-mismatched unrelated grafts (RR 5
2.07; 95% CI; 1.17-3.84; P 5 .02), and HLA-
partially matched unrelated grafts (RR 5 1.85; 95%
CI; 1.13-3.01; P 5 .014) were associated with greater
risk of TRM in multivariate analysis (Table 3).PFS
PFSwas 43% (95%CI5 37%-50%) at 1 year post-
HCT, 32% (95%CI; 26%-37%) at 3 years post-HCT,
and 26% (95% CI; 19%-32%) at 5 years post-
HCT (Figure 1). High-grade histology, use of ATG
(RR 5 1.50; 95% CI; 1.07-2.10; P 5 .020), and
chemotherapy-resistant disease at HCT (RR 5 2.54;
95% CI; 1.50-4.31; P 5 .001) were associated with
higher risk of treatment failure or lower PFS (Table
3). Subjects with Burkitt’s, Burkitt-like, lymphoblastic
(RR 5 2.11; 95% CI; 1.40-3.18; P\ .001), or mantle
Figure 1. OS and PFS for all subjects. Figure 2. PFS by age group and histology.
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gies were at increased risk of treatment failure and
lower PFS (Figure 2). Neither aGVHD nor cGVHD
correlated with PFS. PFS was significantly higher for
subjects transplanted between the ages of 41 years and
60 years, when compared with the older and younger
age groups (Figure 2 and Supplemental Figure 1).Survival
The 100-day mortality rate was 30% (95% CI;
24%-35%). Survival at 1 year post-HCT was 55%
(95% CI; 48%-61%) and 41% (95% CI; 35%-47%)
at 3 years post-HCT (Figure 1). On multivariate
analysis, older age (.60 years) (RR 5 1.77; 95% CI;
1.16-2.70; P 5 .009), use of a non-TBI conditioning
regimen (RR 5 2.17; 95% CI; 1.36-3.48; P 5 .001),
grafts from unrelated mismatched donors (RR 5
2.20; 95% CI; 1.24-3.90; P 5 .007), and female recip-
ients (RR 5 1.47; 95% CI; 1.03-2.10; P 5 .035) were
associated with decreased OS (Table 3). Survival was
superior for those receiving tacrolimus/methotrexate
GVHD prophylaxis compared with those receiving
other GVHD prophylaxis regimens. Use of T cell
depletion was associated with higher risk of death
(RR 5 6.0; 95% CI; 2.68-13.45; P\ .001). Similar
to PFS, subjects between the ages of 41 and 60 had
superior survival compared with other age groups,
and subjects with indolent histologies had improved
survival when compared with those with high or inter-
mediate grade histology NHL (Figure 3 and Supple-
mental Figure 1).Cause of Death
A total of 153 transplant recipients died from
disease recurrence (n 5 40, 26%), organ failure (n 5
29, 19%), GVHD (n 5 23, 15%), infection (n 5 22,
14%), other causes (n 5 21, 14%), pulmonary
syndrome (n 5 12, 8%), hemorrhage (n 5 5, 3%),
and new malignancy (n 5 1,\1%).DISCUSSION
In this cohort of patients with high-risk NHL,
26% (95% CI; 19%-32%) of subjects were alive with-
out disease progression at 5 years after HCT. How-
ever, graft failure, TRM, and disease recurrence were
common obstacles to transplant success. It is impor-
tant to recognize that this study population included
only first allogeneic transplants, and excluded those
who had undergone prior autologous or allogeneic
HCT. Therefore, this population is unique in that
physicians proceeded to HCT with an alternative
donor rather than autologous transplantation. This
analysis studied a patient population at very high-risk
of treatment failure: most were heavily pretreated
leading to resistant disease and a high risk of
transplant-related mortality.
RIC regimens have been proposed to produce
equivalent or superior survival rates when compared
with myeloablative regimens in subjects with myeloid
and lymphoid cancers [13-15], yet published literature
on outcomes of RIC regimens for NHL are limited to
Figure 3. OS by age group and histology.
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22% to 59% at 3 years after HCT, with the best
outcomes observed for indolent histologies. More
aggressive NHL histologies and Hodgkin’s
lymphoma had outcomes approximating 20% [16-19]
PFS. The PFS rates reported in our study compare
favorably to single-center studies reported in the litera-
ture, given the degree of HLA mismatch, poor perfor-
mance status, and extensive prior therapy of our
patient population.
These outcomes, however, are certainly less than
optimal. Although 43% of subjects were alive in remis-
sion at 1 year after HCT, only 26%were free of disease
progression at 5 years post-HCT. Single-institution
studies reporting higher PFS rates generally included
smaller patient numbers and subjects with closer
HLA matching to donors, or included predominately
low-risk NHL such as those with indolent lymphoma
or in remission [15-18]. The low PFS in our cohort
likely results from the high-risk disease, extensive prior
therapy, older median age of this patient population,
and the high graft failure and TRM rates. In this
study, 47% of subjects had chemotherapy-refractory
disease and 31% had a Karnofsky Performance Status
Scale\90.
It is noteworthy that even patients with
chemotherapy-resistant disease are curable in some
instances with RIC regimens followed by allogeneic
HCT [17]. Our study supports the observation that
chemotherapy-resistant disease is a marker for poor
outcome, but should be viewed as a prognostic factor
and not an absolute contraindication to allogeneicHCT.Disease progression occurring before full donor
chimerism may contribute to relapse in patients with
more aggressive histologies, allowing the malignant
cells to outpace the donor immunologic response
[16,18]. In addition, the use of ATG, alemtuzumab,
or T cell–depleted grafts may have delayed lympho-
cyte recovery after HCT, potentially abrogating an
immune-mediated graft-versus-lymphoma effect. Al-
ternatively, delayed immunologic recovery following
HLA-disparate HCT or in the setting of GVHD
may have played a role [20,21], although our data do
not support a potent graft-versus-lymphoma depen-
dent on GVHD.
Disease progression occurred most commonly in
the first year after HCT and was infrequent thereafter.
Acute GVHD or cGVHD did not influence the risk of
disease progression. This observation suggests that
GVHD may not be related to a graft-versus-
lymphoma effect, or that the graft-versus-lymphoma
effect may be more active in certain histologies, and
that this could not be observed because of the wide
variety of indolent and aggressive histologies in this
study [22]. Alternatively, the rates of disease progres-
sion in aggressive histologies may outpace immuno-
logic recovery after HCT so that tumor cells escape
immunologic destruction. As expected, subjects with
more advanced disease andmore aggressive histologies
had greater risks of disease recurrence. Surprisingly,
those transplanted more recently had greater risk of
relapse than those transplanted earlier in the study.
This association of year of HCT and relapse is not
readily explainable, but may reflect the fact that
higher-risk subjects were being transplanted in the
later years of the study as transplant physicians became
more comfortable with these regimens. Alternatively,
this may reflect transplant physician bias, whereby
subjects who may benefit more from myeloablative
regimens receive RIC regimens to decrease TRM.
TRM was 24% at 100 days after HCT and gradu-
ally rose throughout the study period, reaching 43% at
5 years post-HCT, with no evidence of a plateau. Late
TRM was most frequently because of infectious com-
plications or cGVHD. The use of ATG, alemtuzu-
mab, or T cell–depleted grafts, commonly used to
reduce GVHD, may have delayed immune reconstitu-
tion leading to an increased risk of infectious compli-
cations [20]. In our study, infection was responsible
for 22 patient deaths (14%), 8 in ATG recipients.
GVHD also has been reported to be a significant prob-
lem after HCT with an RIC regimen. As expected, an
HLA-mismatched unrelated donor graft source in-
creased the risk of aGVHD. The use of TBI increased
the risk of cGVHD; this effect may be because of thy-
mic damage from TBI that impairs T cell reconstitu-
tion in the thymus after HCT [23]. It is also possible
that patients who received TBI-containing regimens
were more likely to be mixed chimeras following
1042 Biol Blood Marrow Transplant 18:1036-1043, 2012G. A. Hale et al.HCT or that disease control after these regimens was
poorer. Withdrawal of immunosuppressive therapy in
the setting of early disease recurrence could lead to
cGVHD.
Most recipients had neutrophil engraftment by day
100 afterHCT.However, primary and secondary graft
failures were more common than anticipated in this
population undergoing first transplantation. This
may be because of the use of in vivo T cell depletion
agents in the conditioning regimen, the presence of
marrow disease, and/or donor-recipient HLA dispar-
ity. Alternatively, some recipients may have had mar-
row stromal damage, because many of them likely
were unable to undergo autologous HCT, which sug-
gests a mobilization problem in some subjects.
Survival was 55% at 1 year and 35% at 5 years after
HCT. The use of non-TBI conditioning regimens was
associated with poorer OS. It is not readily apparent
why non-TBI regimens were associated with poorer
OS. TBI may have been avoided in subjects who
were heavily pretreated, who had radiation therapy be-
fore HCT, or who had lower performance scores. TBI
in RIC regimens is given to enhance immune suppres-
sion or to prevent graft failure. Both OS and PFS were
counterintuitively lower in the 18- to 40-year-old
group than in the 41- to 59-year-old age group. This
reduced survival may be because of the lower incidence
of follicular lymphomas, which are associated with
a higher survival rate, in this age group. Alternatively,
many studies of adolescent and young adult cancer
patients, defined bymost studies as 15 years to 39 years
old, demonstrate reduced increments in survival for
these patients. Adolescent and young adult patients
have reduced compliance, late diagnosis, lower insur-
ance rates, and may have different biologic character-
istics of their cancers.
Interestingly and perhaps counterintuitively, the
occurrence of aGVHD or cGVHD was not signifi-
cantly correlated with decreased disease recurrence af-
ter HCT. The reasons for this lack of correlation are
not known. The effects of GVHDmay have varied de-
pending on the NHL histologic subtype; subjects with
indolent NHL histologies have been noted in other
reports to have lower disease recurrence rates after
allogeneic HCT. Alternatively, the effect may have
been abrogated because of the high rates of graft fail-
ure or TRM. A graft-versus-lymphoma effect has not
been consistently correlated with GVHD after alloge-
neic HCT, suggesting that it may operate indepen-
dently of GVHD [15,20].
The study is limited by its retrospective nature, and
the underlying reasons behind the clinical decision to
proceed to allogeneic HCT as well as the rationale be-
hind the choice of an RIC regimen are unknown to us.
Many of these recipients had intermediate to advanced
disease and a low performance score (Table 1). These
characteristics suggest that the treating clinicians wereconsidering an RIC regimen to reduce TRM in this
high-risk group. This analysis does not attempt to
compare outcomes of subjects with hematologic ma-
lignancies based on donor–recipient relationship or
HLA-mismatch. Our results suggest that RIC regi-
mens should be considered as a cautious alternative
to myeloablative regimens for NHL subjects undergo-
ing HCT from unrelated or HLA-mismatched related
donors. Future trials should study the use of RIC reg-
imens in pediatric patients and focus on interventions
to further reduce TRM and disease recurrence.ACKNOWLEDGMENTS
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